Literature DB >> 30025731

The SAVI-TF Registry: 1-Year Outcomes of the European Post-Market Registry Using the ACURATE neo Transcatheter Heart Valve Under Real-World Conditions in 1,000 Patients.

Won-Keun Kim1, Christian Hengstenberg2, Michael Hilker3, Sebastian Kerber4, Ulrich Schäfer5, Tanja Rudolph6, Axel Linke7, Norbert Franz8, Thomas Kuntze9, Holger Nef10, Utz Kappert11, Michael O Zembala12, Stefan Toggweiler13, Thomas Walther14, Helge Möllmann15.   

Abstract

OBJECTIVES: The SAVI-TF (Symetis ACURATE neo Valve Implantation Using Transfemoral Access) registry was initiated to study the ACURATE neo transcatheter heart valve in a large patient population treated under real-world conditions.
BACKGROUND: The self-expanding, supra-annular ACURATE neo prosthesis is a transcatheter heart valve that gained the Conformité Européene mark in 2014, but only limited clinical data are available so far.
METHODS: This prospective, multicenter registry enrolled 1,000 patients at 25 European centers who were followed for 1 year post-procedure.
RESULTS: Mean patient age was 81.1 ± 5.2 years; mean logistic European System for Cardiac Operative Risk Evaluation I score, European System for Cardiac Operative Risk Evaluation II score, and Society of Thoracic Surgeons score were 18.1 ± 12.5%, 6.6 ± 7.5%, and 6.0 ± 5.6%, respectively. At 1 year, 8.0% (95% confidence interval [CI]: 6.3% to 9.7%) of patients had died, 2.3% (95% CI: 1.3% to 3.2%) had disabling strokes, and 9.9% (95% CI: 8.1% to 11.8%) had permanent pacemaker implantations. Through 1 year, 5 reinterventions (0.5%; 95% CI: 0.1% to 1.0%) were performed: 3 valve-in-valve and 2 surgical aortic valve replacements. Mean effective orifice area was 1.84 ± 0.43 cm2, mean gradient was 7.3 ± 3.7 mm Hg, and greater than mild paravalvular leakage was observed in 3.6% of patients.
CONCLUSIONS: Transfemoral implantation of the ACURATE neo prosthesis resulted in favorable 1-year clinical and echocardiographic outcomes with very low mortality and new pacemaker rates.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACURATE neo; TAVR; aortic stenosis; transcatheter aortic valve replacement; transfemoral

Mesh:

Year:  2018        PMID: 30025731     DOI: 10.1016/j.jcin.2018.03.023

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  11 in total

Review 1.  Intraventricular Conduction Disturbances After Transcatheter Aortic Valve Implantation.

Authors:  Shu-I Lin; Mizuki Miura; Ana Paula Tagliari; Ying-Hsian Lee; Shinichi Shirai; Rishi Puri; Francesco Maisano; Maurizio Taramasso
Journal:  Interv Cardiol       Date:  2020-07-29

2.  One-year clinical outcome with a novel self-expanding transcatheter heart valve.

Authors:  Costanza Pellegrini; Tobias Rheude; Teresa Trenkwalder; N Patrick Mayr; Jonathan Michel; Adnan Kastrati; Heribert Schunkert; Albert M Kasel; Michael Joner; Christian Hengstenberg; Oliver Husser
Journal:  Catheter Cardiovasc Interv       Date:  2019-02-24       Impact factor: 2.692

3.  Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation.

Authors:  Albert H Kim; Steven Tatter; Ganesh Rao; Sujit Prabhu; Clark Chen; Peter Fecci; Veronica Chiang; Kris Smith; Brian J Williams; Alireza M Mohammadi; Kevin Judy; Andrew Sloan; Zulma Tovar-Spinoza; James Baumgartner; Constantinos Hadjipanayis; Eric C Leuthardt
Journal:  Neurosurgery       Date:  2020-09-01       Impact factor: 4.654

Review 4.  An Update on New Generation Transcatheter Aortic Valves and Delivery Systems.

Authors:  Gloria Santangelo; Alfonso Ielasi; Mariano Pellicano; Azeem Latib; Maurizio Tespili; Francesco Donatelli
Journal:  J Clin Med       Date:  2022-01-19       Impact factor: 4.241

5.  Transcatheter Aortic Valve Implantation with ACURATE neo: Results from the PROGRESS PVL Registry.

Authors:  Won-Keun Kim; Holger Thiele; Axel Linke; Thomas Kuntze; Stephan Fichtlscherer; John Webb; Michael W A Chu; Matti Adam; Gerhard Schymik; Tobias Geisler; Rajesh Kharbanda; Thomas Christen; Dominic Allocco
Journal:  J Interv Cardiol       Date:  2022-06-25       Impact factor: 1.776

6.  Transcatheter treatment of native aortic valve regurgitation: Results from an international registry using the transfemoral ACURATE neo valve.

Authors:  Paola Angela Maria Purita; Luisa Salido Tahoces; Chiara Fraccaro; Luca Nai Fovino; Won-Keun Kim; Cláudio Espada-Guerreiro; Ole De Backer; Morritz Seiffert; Luis Nombela-Franco; Raul Moreno Gomez; Antonio Mangieri; Anna Franzone; Francesco Bedogni; Fausto Castriota; Tiziana Attisano; Lars Søndergaard; Rosana Hernandez Antolin; Giuseppe Tarantini
Journal:  Int J Cardiol Heart Vasc       Date:  2020-02-12

7.  Predictors of paravalvular leak following implantation of the ACURATE neo transcatheter heart valve: the PREDICT PVL study.

Authors:  Miriam Brinkert; Bart De Boeck; Simon F Stämpfli; Mathias Wolfrum; Federico Moccetti; Adrian Attinger-Toller; Matthias Bossard; Florim Cuculi; Richard Kobza; Stefan Toggweiler
Journal:  Open Heart       Date:  2020-11

Review 8.  ACURATE neo: How Is This TAVR Valve Doing to Fit into an Increasingly Crowded Field?

Authors:  Taishi Okuno; Jonas Lanz; Thomas Pilgrim
Journal:  Curr Cardiol Rep       Date:  2020-08-08       Impact factor: 2.931

Review 9.  Choice of transcatheter heart valve: should we select the device according to each patient's characteristics or should it be "one valve fits all"?

Authors:  Matthias Renker; Won-Keun Kim
Journal:  Ann Transl Med       Date:  2020-08

10.  The ACURATE neo2 valve system for transcatheter aortic valve implantation: 30-day and 1-year outcomes.

Authors:  Helge Möllmann; David M Holzhey; Michael Hilker; Stefan Toggweiler; Ulrich Schäfer; Hendrik Treede; Michael Joner; Lars Søndergaard; Thomas Christen; Dominic J Allocco; Won-Keun Kim
Journal:  Clin Res Cardiol       Date:  2021-06-20       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.